{
    "symbol": "ADPT",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 19:04:09",
    "content": " Total revenue in the first quarter was $38.6 million, representing a slight increase from $38.4 million in the same period last year. Immune medicine revenue in the first quarter was $20.8 million, a 4% increase from the same period in 2021. MRD revenue was $17.8 million in the first quarter, down 3% from the same period last year. Total operating expenses for the first quarter of 2022 were $101.7 million, representing a 28% increase of $79.7 million in the same quarter last year. Cost of revenue was $13.2 million during the first quarter of 2022, compared to $10 million for the first quarter last year, representing a 32% increase. Higher cost of revenue was primarily driven by an increase in material cost, due to revenue simple volume growth and an increase in labor, overhead  16:35 Research and development expenses for the first quarter of \u201922 were $37.8 million, compared to $33.8 million in the first quarter 2021, representing a 12% increase. 16:54 Sales and marketing expenses for the first quarter of 2022 were $26.1 million, compared to $20.6 million of the first quarter of 2021, representing an increase of 27%. 17:28 General and administrative expenses for the first quarter of 2022, were $24.1 million, compared to $14.9 million in the first quarter of 2021, representing an increase of 62%. Your line is open. The first thing the MRD milestones and just as a reminder, in Q1 of last year, we had approximately $7 million of milestones from our MRD business and this quarter we have $3 million, so we\u2019re seeing $4 million in compression there from a comp perspective. Your line is open. Your line is open. Your line is open. Your line is open."
}